IMBdx Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Public

  • Employees
  • 57

Employees

  • Stock Symbol
  • 461030

Stock Symbol

  • Share Price
  • $10.53
  • (As of Tuesday Closing)

IMBdx General Information

Description

IMBdx Inc detects and analyzes the genomic profile of tumor DNA with a single draw of blood. It provides personalized and optimized analysis information that can be utilized in therapy selection and monitoring. Its AlphaLiquid platform offers ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection (AlphaLiquid 100/HRR) to recurrence and minimal residual disease(MRD) monitoring (CancerDetect), and multi-cancer early detection (CancerFind). Its services are Clinical Service BioPharma, Research, and Healthcare Checkup.

Contact Information

Website
www.imbdx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 131 Gasan Digital 1-ro, Geumcheon-gu
  • 21st Floor, Building A, BYC High City Building
  • Seoul, 08506
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
KRX
Vertical(s)
LOHAS & Wellness, HealthTech, Life Sciences, Oncology
Corporate Office
  • 131 Gasan Digital 1-ro, Geumcheon-gu
  • 21st Floor, Building A, BYC High City Building
  • Seoul, 08506
  • South Korea
+82

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

IMBdx Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$10.53 $10.80 $6.09 - $29.98 $148M 14M 1.4M -$0.52

IMBdx Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
Revenue 3,330 3,080 2,031 1,074
EBITDA (5,977) (6,149) (5,905) (7,047)
Net Income (7,494) (7,967) (8,077) (8,546)
Total Assets 30,260 7,621 13,738 20,195
Total Debt 190 249 193 168
Public Fundamental Data provided by Morningstar, Inc. disclaimer

IMBdx Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore IMBdx‘s full profile, request access.

Request a free trial

IMBdx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
IMBdx Inc detects and analyzes the genomic profile of tumor DNA with a single draw of blood. It provides personalized an
Drug Discovery
Seoul, South Korea
57 As of 2024

Cambridge, MA
 

Palo Alto, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

IMBdx Competitors (5)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Foundation Medicine Formerly VC-backed Cambridge, MA
Guardant Health Formerly VC-backed Palo Alto, CA
Natera Formerly VC-backed Austin, TX
GRAIL Formerly VC-backed Menlo Park, CA
Freenome Venture Capital-Backed San Francisco, CA
You’re viewing 5 of 5 competitors. Get the full list »

IMBdx Patents

IMBdx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4282984-A1 Method for construction of multi-feature prediction model for cancer diagnosis Pending 29-Mar-2022
EP-4287213-A1 Method for predicting cancer recurrence using patient-specific panel Pending 29-Mar-2022
US-20240318253-A1 Method of predicting cancer recurrence using patient-specific panel Pending 29-Mar-2022
US-20240312563-A1 Method for preparation of multi-analytical prediction model for cancer diagnosis Pending 29-Mar-2022
US-20240296905-A1 Method of identifying false positive variants in nucleic acid sequencing Pending 21-Mar-2022 G16B20/20
To view IMBdx’s complete patent history, request access »

IMBdx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

IMBdx Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore IMBdx‘s full profile, request access.

Request a free trial

IMBdx FAQs

  • When was IMBdx founded?

    IMBdx was founded in 2018.

  • Where is IMBdx headquartered?

    IMBdx is headquartered in Seoul, South Korea.

  • What is the size of IMBdx?

    IMBdx has 57 total employees.

  • What industry is IMBdx in?

    IMBdx’s primary industry is Drug Discovery.

  • Is IMBdx a private or public company?

    IMBdx is a Public company.

  • What is IMBdx’s stock symbol?

    The ticker symbol for IMBdx is 461030.

  • What is the current stock price of IMBdx?

    As of 05-Nov-2024 the stock price of IMBdx is $10.53.

  • What is the current market cap of IMBdx?

    The current market capitalization of IMBdx is $148M.

  • What is IMBdx’s current revenue?

    The trailing twelve month revenue for IMBdx is $3.33M.

  • Who are IMBdx’s competitors?

    Foundation Medicine, Guardant Health, Natera, GRAIL, and Freenome are competitors of IMBdx.

  • What is IMBdx’s annual earnings per share (EPS)?

    IMBdx’s EPS for 12 months was -$0.52.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »